CAS 1051375-10-0
:Cabotegravir
Description:
Cabotegravir is an antiretroviral medication primarily used in the treatment and prevention of HIV infection. It belongs to the class of drugs known as integrase strand transfer inhibitors (INSTIs), which work by inhibiting the integrase enzyme, crucial for the integration of viral DNA into the host cell's genome. This action helps prevent the replication of the virus. Cabotegravir is notable for its long-acting formulation, which can be administered via intramuscular injection, allowing for extended dosing intervals compared to daily oral medications. The substance is characterized by its high potency and specificity for the HIV integrase enzyme, contributing to its effectiveness in both treatment and pre-exposure prophylaxis (PrEP). Additionally, cabotegravir has a favorable safety profile, with common side effects including injection site reactions and mild gastrointestinal disturbances. Its development represents a significant advancement in HIV management, offering patients more flexible treatment options and improving adherence to therapy.
Formula:C19H17F2N3O5
InChI:InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
InChI key:InChIKey=WCWSTNLSLKSJPK-LKFCYVNXSA-N
SMILES:O=C1C=2N(C[C@@]3(N1[C@@H](C)CO3)[H])C=C(C(NCC4=C(F)C=C(F)C=C4)=O)C(=O)C2O
Synonyms:- (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- (3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
- Cabotegravir
- Gsk 1265744A
- Gsk 744
- Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Cabotegravir (GSK744, GSK1265744)
CAS:Formula:C19H17F2N3O5Purity:98%Color and Shape:SolidMolecular weight:405.3522(3S,11Ar)-N-(2,4-Difluorobenzyl)-6-Hydroxy-3-Methyl-5,7-Dioxo-2,3,5,7,11,11A-Hexahydrooxazolo[3,2-A]Pyrido[1,2-D]Pyrazine-8-Carboxamide
CAS:<p>(3S,11Ar)-N-(2,4-Difluorobenzyl)-6-Hydroxy-3-Methyl-5,7-Dioxo-2,3,5,7,11,11A-Hexahydrooxazolo[3,2-A]Pyrido[1,2-D]Pyrazine-8-Carboxamide</p>Purity:98%Molecular weight:405.35g/molCabotegravir
CAS:<p>Cabotegravir (S/GSK1265744) (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (</p>Formula:C19H17F2N3O5Purity:98.55% - 99.92%Color and Shape:SolidMolecular weight:405.35Cabotegravir
CAS:<p>Applications Cabotegravir is a long acting HIV-1 integrase inhibitor with action against a broad range of HIV subtypes.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Yoshinaga, T. et al.: Antimicrob, Agents Chemother., 59, 397 (2015); Andrews, C. et al.: Sci. Transl. Med., 7, 270 (2015);<br></p>Formula:C19H17F2N3O5Color and Shape:Off-WhiteMolecular weight:405.35Cabotegravir-d3
CAS:Controlled ProductFormula:C19H14D3F2N3O5Color and Shape:NeatMolecular weight:408.37Cabotegravir
CAS:<p>Anti-viral; HIV integrase inhibitor</p>Formula:C19H17F2N3O5Purity:Min. 95%Color and Shape:White/Off-White SolidMolecular weight:405.35 g/mol(3S,11aR)-3-Methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid
CAS:Formula:C12H12N2O5Purity:95.0%Molecular weight:264.237
![(3S,11aR)-3-Methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxy…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F10%2Fthumb%2FF533686.jpg&w=3840&q=75)
